Established in 1995, the Department of Hematology and Oncology has continuously gained vitality and grown alongside the hospital's reforms and innovations. It currently has 100 beds, staffed by 4 professors, 1 chief technologist, 2 associate professors, 10 medical doctors, and 4 returnees who pursued further studies or research in the United States and Canada. The department specializes in the treatment of malignant solid tumors and various hematological diseases. Guided by the principles of evidence-based medicine, it collaborates with multiple disciplines including surgery, radiotherapy, interventional medicine, pathology, and the central laboratory to provide multidisciplinary care. For each admitted patient, staging is determined based on comprehensive relevant examinations. Treatment plans are developed according to the best standardized comprehensive protocols, referencing guidelines such as the US NCCN guidelines and Chinese guidelines for the standardized treatment of solid tumors. The department actively advocates for the application of new technologies and therapies, providing high-standard, high-quality services from the outset.

For various solid tumors, including lung cancer, liver cancer, gastric cancer, colorectal cancer, breast cancer, endometrial cancer, ovarian cancer, and soft tissue tumors, the department explores the biological behavior and clinical characteristics of tumor cells and adopts internationally standardized chemotherapy regimens to provide patients with optimal and standardized treatment. Combined chemotherapy is often complemented by comprehensive measures such as cytokine therapy, immunotherapy, endocrine therapy, and traditional Chinese medicine therapy. Particularly in recent years, with rapid scientific advancements, molecular targeted therapy has been widely applied in clinical practice. For instance, for non-small cell lung cancer, drugs such as gefitinib (Iressa), erlotinib (Tarceva), and the multi-target drug pemetrexed are used, achieving remarkable efficacy. For breast cancer treatment, greater emphasis is placed on endocrine therapy and molecular targeted therapy alongside combined chemotherapy. "Personalized" treatment is tailored to individual patients, with extensive experience accumulated in using drugs such as trastuzumab (Herceptin), aromatase inhibitors like anastrozole, and exemestane.

The department also places special emphasis on preoperative neoadjuvant chemotherapy, postoperative consolidation chemotherapy, intracavitary chemotherapy, and palliative chemotherapy for patients in need. It was the first in the province to apply tumor gene chip diagnostic technology clinically, enabling dynamic observation of tumor cell metabolism and changes in patients. This technology also aids in diagnosing malignant tumors and monitoring treatment efficacy, providing reliable basis for clinical decision-making. For the treatment of bone metastases, the combination of chemotherapy with bisphosphonates, inhibitors of osteoclast precursors, has enabled many advanced cancer patients to regain mobility and a new lease on life. For patients with massive effusions due to pleural, peritoneal, or pericardial cavity metastases, catheter drainage combined with triple-drug alternating therapy (chemotherapy drugs, traditional Chinese medicine, interleukin, etc.) has achieved remission in most cases. Additionally, in clinical practice, focus is placed on addressing and managing conditions such as superior vena cava syndrome, spinal cord compression, hypercalcemia, and tumor lysis syndrome in advanced cancer patients, alleviating suffering and improving quality of life.

In the treatment of hematological diseases, the department primarily manages various anemias (iron deficiency anemia, hemolytic anemia, megaloblastic anemia), myelodysplastic syndrome (MDS), acute and chronic leukemias, malignant lymphomas, multiple myeloma, myeloproliferative diseases (polycythemia vera, myelofibrosis), thrombocytopenic purpura, and hemophilia. To enhance the diagnosis and treatment of hematological diseases, in addition to peripheral blood and bone marrow morphological diagnosis, the department has successively introduced bone marrow pathological diagnosis, bone marrow chromosome analysis, cytochemical staining, leukemia immunophenotyping, and fusion gene detection.

In leukemia treatment, besides traditional chemotherapy, molecular targeted therapy is also implemented. A successful example in the treatment of malignant hematological diseases is acute promyelocytic leukemia (APL), where arsenic trioxide combined with chemotherapy and sequential therapy has achieved a 100% remission rate with no recurrence. For chronic myeloid leukemia, characterized by the BCR/ABL fusion gene resulting from chromosomal translocation and expressing the highly tyrosine kinase-active p210 protein, imatinib mesylate (Gleevec) is used as first-line treatment. It highly specifically inhibits the leukemia fusion gene, achieving high rates of hematological and cytogenetic remission in treated CML patients. In the treatment of malignant lymphoma, the application of monoclonal antibodies has led to breakthrough progress. For non-Hodgkin's B-cell lymphoma, the CHOP regimen combined with rituximab (MabThera) significantly improves complete remission rates and prolongs disease-free survival. Rituximab has also shown good efficacy in treating refractory immune thrombocytopenic purpura.

The hematology laboratory currently has 5 staff members, including 1 chief technologist, 1 attending physician, 1 technologist-in-charge, 1 technician, and 1 nurse-in-charge. Equipment includes one Olympus BX53 quintuple viewing microscope, one ultra-high magnification microscopic analyzer, two sets of bone marrow cell microscopic image analysis systems, three Olympus optical microscopes, one Leica microtome, and one multi-tumor marker protein chip detector. The laboratory performs routine tests such as bone marrow cell morphology examination, bone marrow cell cytochemical staining, bone marrow pathological diagnosis, and peripheral blood smear analysis. The "multifunctional ultra-high magnification microscopic analyzer" boasts a resolution of up to 0.3μm, enabling direct observation of cells, pathogenic microorganisms, and other formed elements in blood, body fluids, and secretions, providing basis for disease diagnosis, treatment, and monitoring of sub-health conditions. The department's "multi-tumor marker protein chip detection" project, the first of its kind in the three northeastern provinces, simultaneously detects twelve tumor markers: AFP, CEA, CA125, CA153, NSE, CA19-9, CA242, PSA, Free-PSA, β-HCG, Ferritin, and HGH. This provides significant reference value for the diagnosis of malignant tumors, disease staging, efficacy monitoring, and prognosis.

The Department of Hematology and Oncology is a master's degree program in internal medicine under the Jilin University Medical College, directly under the Ministry of Education. It serves as a provincial continuing education base and a national clinical pharmacology base, and undertakes provincial remote medical consultation tasks. The department has successively undertaken and completed 14 projects from the Jilin Provincial Department of Science and Technology, 1 major project from the National Ministry of Science and Technology, 5 projects from the Changchun Municipal Bureau of Science and Technology, and 9 horizontal collaborative projects. It has published over 80 papers in core journals, including more than 10 SCI-indexed papers. The department has received one second prize and one third prize of the Jilin Provincial Science and Technology Progress Award, and 4 Jilin University Medical Achievement Awards. In recent years, 4 personnel have pursued further studies and research at the University of Louisville, Thomas Jefferson University, and the University of Alberta. Additionally, the department focuses on continuous self-improvement and updating of前沿知识 (cutting-edge knowledge). It regularly participates in top international and domestic academic conferences, including ASCO, CSCO, and ASH, staying abreast of the latest advancements. The department frequently organizes provincial, university-level, and hospital-level continuing medical education, sharing hematology-specific knowledge relevant to other departments. Regular small lectures are held within the department to continuously improve medical standards, and the most advanced treatment concepts are integrated into daily medical practice.

The Department of Hematology and Oncology is a team possessing superb diagnostic and therapeutic technical skills and rich clinical experience. With a良好的住院环境 (good inpatient environment) and周到服务理念 (thoughtful service philosophy), it is dedicated to serving patients with hematological and oncological diseases.